モノカルボン酸トランスポーター 8 欠損症患者におけるティラトリコールの利用拡大プログラム
アラン・ハーンドン・ダドリー症候群（AHDS）としても知られるモノカルボン酸トランスポーター8欠損症患者におけるティラトリコールの利用拡大プログラム
The goal of this program is to provide expanded access (i.e., before marketing authorization) to tiratricol as treatment for patients with monocarboxylate transporter 8 deficiency (MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome [AHDS]), who in their Treating Physician's opinion, could benefit from tiratricol and meet the eligibility criteria.
調査の概要
詳細な説明
This will be an open-label, single-arm, multi-center EAP, designed to provide treatment access in the US to tiratricol for eligible patients with MCT8 deficiency, also known as AHDS.
Patients will undergo clinical and safety assessments before tiratricol treatment initiation, during the titration phase and then at approximately 3-6 monthly intervals or more frequently if clinically indicated, following the initiation of tiratricol treatment and until treatment is completed or discontinued.
Adverse events (AEs) and serious adverse events (SAEs) will be recorded and reported as per FDA regulations.
研究の種類
拡張アクセス タイプ
- 中規模人口
- 治療IND/プロトコル
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35249
- University of Alabama at Birmingham Hospital
-
-
California
-
Madera、California、アメリカ、93636-8762
- Valley Children's Hospital
-
San Diego、California、アメリカ、92123
- Rady Children's Hospital
-
-
Florida
-
Jacksonville、Florida、アメリカ、32207
- Nemour's Children Hospital
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30329
- Children's Healthcare of Atlanta
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70118
- Louisiana State University Health Sciences Center and Children's Hospital
-
-
Massachusetts
-
Springfield、Massachusetts、アメリカ、01199
- Baystate Medical Center
-
-
Minnesota
-
Saint Paul、Minnesota、アメリカ、55101
- Gillette's Children's Specialty Healthcare
-
-
New York
-
New York、New York、アメリカ、10029
- Icahn School of Medicine at Mount Sinai
-
New York、New York、アメリカ、10032
- Columbia University Irving Medical Center
-
-
Oregon
-
Portland、Oregon、アメリカ、97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- Children's Hospital of Philadelphia
-
-
Tennessee
-
Memphis、Tennessee、アメリカ、38105
- Le Bonheur Children's Hospital Foundation
-
-
Texas
-
Fort Worth、Texas、アメリカ、76106
- Cook Children's Health Care System
-
-
Washington
-
Tacoma、Washington、アメリカ、98403
- MultiCare Mary Bridge Children's Hospital
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53326
- Children's Wisconsin
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Each patient must meet all of the following criteria to be eligible:
- Diagnosis of MCT8 deficiency confirmed with a genetic test.
- Either tiratricol treatment naïve, or patients who may be on a stable dose of tiratricol having transferred from the Phase 3 MCT8-2021-3 (ReTRIACt) study (NCT05579327) or prior individual investigational new drug (IND).
- In the Treating Physician's medical opinion, the potential benefits of treatment with tiratricol outweigh the potential risks for the patient.
- Patient or legal representative provided signed and dated informed consent to be treated with tiratricol, through this EAP.
- Given the severity of the disease, sexual activity in these patients is deemed unlikely. However, where, at the discretion of the Treating Physician sexual activity is possible for the patient, patients must follow protocol-specified-contraception guidance.
- Patient is approved for enrolment by the sponsor RTT.
Exclusion Criteria:
Patients who meet any of the following criteria will be excluded from the EAP:
-
Parents, legal representative or, if applicable, patients unwilling or unable to comply with the Treating Physician's treatment plan related to this EAP for any reason.
-
Major illness or recent major surgery unrelated to MCT8 deficiency (in the Treating Physician's judgement), defined as:
- Conditions requiring repeated hospitalizations that are likely to confound ability to participate in the program.
- Major illness in the 3 months before the screening visit that is likely to confound the ability of the patient to participate fully within the program and/or confound the assessment of serum total T3 and/or safety.
- Major surgery within the 3 months before the screening visit, or planned to take place during the program, including but not limited to major abdominal/thoracic/neurosurgical procedures.
- Major/minor abdominal and/or maxillofacial surgery that may inhibit the administration and/or absorption of tiratricol.
-
Patients with any contra-indication for treatment with tiratricol or any excipients in the program treatment.
-
Patients using thyroid hormone analogues- such as levothyroxine -or thionamides, such as propylthiouracil. Prior use of these drugs is not an exclusion criterion, provided the use of the medication has subsided and the thyroid hormone levels have stabilized after the cessation of these medications. For patients currently using these medications the switch to tiratricol should be made following the above and under the guidance of an endocrinologist with knowledge of MCT8 deficiency, if needed, after consultation with pharmacologist.
-
Known hypersensitivity to tiratricol including any ingredient in the pharmaceutical formulation.
-
Although very unlikely, as this is a severe X-linked disease: Women who are nursing or pregnant (or women who are planning to become pregnant during treatment with tiratricol).
-
Patients eligible for clinical trials with tiratricol.
研究計画
研究はどのように設計されていますか？
協力者と研究者
出版物と役立つリンク
一般刊行物
- Groeneweg S, Peeters RP, Moran C, Stoupa A, Auriol F, Tonduti D, Dica A, Paone L, Rozenkova K, Malikova J, van der Walt A, de Coo IFM, McGowan A, Lyons G, Aarsen FK, Barca D, van Beynum IM, van der Knoop MM, Jansen J, Manshande M, Lunsing RJ, Nowak S, den Uil CA, Zillikens MC, Visser FE, Vrijmoeth P, de Wit MCY, Wolf NI, Zandstra A, Ambegaonkar G, Singh Y, de Rijke YB, Medici M, Bertini ES, Depoorter S, Lebl J, Cappa M, De Meirleir L, Krude H, Craiu D, Zibordi F, Oliver Petit I, Polak M, Chatterjee K, Visser TJ, Visser WE. Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 2019 Sep;7(9):695-706. doi: 10.1016/S2213-8587(19)30155-X. Epub 2019 Jul 31.
- van Geest FS, Groeneweg S, van den Akker ELT, Bacos I, Barca D, van den Berg SAA, Bertini E, Brunner D, Brunetti-Pierri N, Cappa M, Cappuccio G, Chatterjee K, Chesover AD, Christian P, Coutant R, Craiu D, Crock P, Dewey C, Dica A, Dimitri P, Dubey R, Enderli A, Fairchild J, Gallichan J, Garibaldi LR, George B, Hackenberg A, Heinrich B, Huynh T, Klosowska A, Lawson-Yuen A, Linder-Lucht M, Lyons G, Monti Lora F, Moran C, Muller KE, Paone L, Paul PG, Polak M, Porta F, Reinauer C, de Rijke YB, Seckold R, Menevse TS, Simm P, Simon A, Spada M, Stoupa A, Szeifert L, Tonduti D, van Toor H, Turan S, Vanderniet J, de Waart M, van der Wal R, van der Walt A, van Wermeskerken AM, Wierzba J, Zibordi F, Zung A, Peeters RP, Visser WE. Long-Term Efficacy of T3 Analogue Triac in Children and Adults With MCT8 Deficiency: A Real-Life Retrospective Cohort Study. J Clin Endocrinol Metab. 2022 Feb 17;107(3):e1136-e1147. doi: 10.1210/clinem/dgab750.
研究記録日
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- Tiratricol-EAP-Pro MCT8-2022-4
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。